Yes, people with polycythemia can donate blood in selected cases, but standard volunteer donation is usually not the right channel; the safe path is a prescribed therapeutic phlebotomy supervised by a hematologist. Acceptance depends on the cause, hematocrit, symptoms, medicines, and local blood-center policy. In polycythemia vera, phlebotomy is treatment, so the unit may be discarded or used only through an FDA-labeled therapeutic donor program. For secondary polycythemia, a blood center may accept you if your hemoglobin is within donor limits and you have no deferral condition.
Why Polycythemia Changes Blood Donation
Polycythemia is not one disease. It is a group of disorders that raise red-cell mass, and that distinction decides whether a blood center can treat you as a routine donor. In polycythemia vera, a JAK2 mutation drives the bone marrow to overproduce red cells, white cells, and platelets. In secondary polycythemia, low oxygen, smoking, sleep apnea, high altitude, or excess erythropoietin pushes the marrow to make more red cells. The hematocrit is the percentage of blood volume occupied by red cells, and it is the number most blood centers and hematologists use for triage.
Whole-blood viscosity rises steeply as hematocrit climbs above the normal range. At a hematocrit of 60%, viscosity can be roughly twice that at 45%, which increases resistance to flow in small vessels. That is why symptoms can include headache, blurred vision, flushing, fatigue, and thrombosis. A 450-500 mL phlebotomy removes about 200-250 mg of iron and roughly 10% of circulating red-cell mass in an average adult. The plasma volume refills within 24-48 hours, so the hematocrit may not fall immediately; it drops as the remaining red cells are diluted.
A standard blood donation is designed for a healthy volunteer. The donor must meet hemoglobin and hematocrit limits, pass a health questionnaire, and wait about 56 days between whole-blood donations in the United States. Those rules protect the donor from anemia and protect the recipient from transmission of disease. They are not designed to deliver rapid, repeated red-cell reduction for someone with a myeloproliferative neoplasm. In plain terms: a donation is a public gift, while therapeutic phlebotomy is a prescribed treatment with a target number.
Can You Donate Blood With Polycythemia? The Rules
The short rule is this: you may be able to donate through a therapeutic donor program, but not by walking into a standard blood drive and saying you have polycythemia. A blood center will usually defer a donor with a known diagnosis of polycythemia vera unless it has a specific protocol and a physician's prescription. For secondary polycythemia, acceptance is more variable. The center will check your hemoglobin, hematocrit, blood pressure, medications, travel history, and infection risks. Some centers will collect the unit and discard it; others can transfuse it if the unit meets FDA-labeled therapeutic donor criteria.
| Feature | Standard volunteer donation | Therapeutic phlebotomy for polycythemia |
|---|---|---|
| Main purpose | Community blood supply | Lower red-cell mass and hematocrit |
| Who orders it | Donor volunteers | Hematologist or other treating clinician |
| Typical volume | 450-500 mL | 400-500 mL, often 450-500 mL |
| Typical interval | Every 56 days in the US | Every 2-4 days during induction; every 2-3 months in maintenance |
| Target | Donor hemoglobin limits | Hematocrit below 45%, or below 42% at some centers for women |
| Blood use | Transfused if eligible | Discarded or transfused only under a therapeutic donor protocol |
| Monitoring | Hemoglobin check before donation | Hematocrit, platelets, symptoms, and ferritin over time |
The prescription should state the diagnosis, target hematocrit, volume, and interval. The center must decide whether the unit can be labeled for transfusion or must be discarded. A 450-500 mL unit at a hematocrit of 50% contains about 225-250 mL of red cells, or roughly 225-250 mg of iron. A standard 56-day interval is too slow for induction, when hematocrit may need to fall by 5-10 percentage points over 2-6 weeks. The rules are not uniform: US blood centers set local policies within FDA and AABB requirements.
If you have a hematocrit of 54% or higher, do not try to solve it by donating at a blood drive. A level that high deserves a clinical review, because it can signal severe erythrocytosis, dehydration, or a myeloproliferative neoplasm. The blood center is not your diagnostic service. It is a collection site with its own eligibility rules and its own responsibility to protect the blood supply.
Polycythemia Vera vs Secondary Polycythemia
Polycythemia vera is a clonal marrow disease. About 95% of PV cases carry JAK2 V617F, and another 3-5% have JAK2 exon 12 mutations. The 2016 WHO criteria use hemoglobin above 16.5 g/dL in men or 16.0 g/dL in women, or hematocrit above 49% in men or 48% in women, as major thresholds. PV also causes low erythropoietin, splenomegaly, thrombocytosis, and a high risk of arterial and venous thrombosis. In PV, phlebotomy is a treatment, and the target is usually hematocrit below 45%. The CYTO-PV trial, published in 2013, found that a target below 45% reduced major thrombotic events compared with a target of 45-50%. Some centers use below 42% for women because normal hematocrit is lower in women.
Secondary polycythemia is different. It is the marrow responding to a signal, such as chronic hypoxia from COPD, sleep apnea, or living at 8,000 feet or higher. Smoking can raise carboxyhemoglobin and cause a compensatory rise in red cells. Renal tumors and exogenous erythropoietin can also drive production. In secondary polycythemia, the first treatment is the cause: stop smoking, treat sleep apnea with CPAP, correct hypoxemia, or stop unnecessary erythropoietin. A blood center may accept a person with mild secondary polycythemia if the hemoglobin is within donor limits and there is no deferral condition. A hematocrit above 54% in men or above 49% in women is a red flag for urgent evaluation, not a reason to self-donate.
Donor eligibility limits are different from diagnostic thresholds. Donor centers often use hemoglobin 12.5-18.0 g/dL, with local sex-specific cutoffs. These limits are not the same as the WHO diagnostic thresholds above. A person can meet a diagnostic threshold for polycythemia and still be deferred by a blood center. A person can also have a high hemoglobin from dehydration and be temporarily deferred until the number normalizes.
Therapeutic Phlebotomy Timeline
The time course depends on the diagnosis and the starting hematocrit. Induction is faster than maintenance. The table shows a common pattern for PV; secondary polycythemia may need less frequent phlebotomy if the cause is corrected.
| Time point | What happens | Typical numbers |
|---|---|---|
| Before first procedure | Confirm diagnosis, check JAK2, erythropoietin, platelets, ferritin, and oxygen saturation | Target hematocrit usually below 45%; below 42% for women at some centers |
| Day 0 | Remove one unit of whole blood with a prescription and monitoring | 400-500 mL; about 200-250 mg iron removed |
| 24-48 hours | Plasma volume refills; hematocrit falls as remaining cells are diluted | Hydrate; avoid heavy exercise for 24 hours |
| Every 2-4 days during induction | Repeat phlebotomy until the target is reached | 450-500 mL per session; check CBC before each session |
| Every 2-3 months during maintenance | Check hematocrit and phlebotomize when above target | Most patients need 3-6 sessions per year, but ranges vary |
| 3-6 months | Check ferritin and blood counts; assess symptoms and thrombosis risk | Ferritin below 15-20 ng/mL suggests iron deficiency |
| Long term | Reassess need for cytoreduction, especially if phlebotomy is frequent | Phlebotomy every 4-8 weeks may prompt hydroxyurea or other therapy |
In PV, induction often requires 3-6 sessions over 1-3 weeks. A 450-500 mL phlebotomy lowers hematocrit by about 2-3 percentage points after plasma refill in many adults. The exact drop depends on starting blood volume, body size, and how quickly plasma refills. Maintenance is slower: many patients need a phlebotomy every 2-3 months, while others need one every 4-8 weeks. The frequency is driven by the hematocrit trend, not by a fixed calendar.
Risks, Misconceptions, and Iron Traps
One common misconception is that high hematocrit means high iron. In PV, iron stores are often normal or low, especially after repeated phlebotomy. Each 450-500 mL unit removes about 200-250 mg of iron, and 10 sessions can remove 2,000-2,500 mg. The body stores only about 1,000 mg in men and 300-500 mg in women, so iron deficiency is common during maintenance. That iron deficiency can make red cells small and lower the measured hematocrit even when red-cell mass remains high. In plain terms: a falling hematocrit is not always a falling red-cell mass; it can be a falling red-cell size.
Another misconception is that donation cures polycythemia. Phlebotomy controls hematocrit but does not remove the JAK2 clone in PV. It also does not fix the cause of secondary polycythemia. Patients with PV still need monitoring for thrombosis, bleeding, and transformation to myelofibrosis or acute leukemia. The risk of transformation is about 1-2% per year for myelofibrosis and lower for acute leukemia, but it is not zero. Phlebotomy can cause fatigue, hypotension, syncope, and vasovagal reactions, especially in older adults or people with heart disease. Rapid large-volume phlebotomy without monitoring is unsafe.
A third misconception is that a therapeutic phlebotomy is always used for transfusion. Many centers discard the unit because the donor has a disease that would otherwise defer them. Some centers participate in FDA-reviewed therapeutic donor programs and can transfuse the unit if it meets labeling and testing rules. The logistics matter: a discarded unit costs the center money, while a transfused unit requires additional testing and tracking. Cost varies by center, but a therapeutic phlebotomy session may be billed at USD 50-200 or more in the United States, and insurance coverage varies.
What to Actually Do Before You Donate
Start by getting the diagnosis confirmed. Ask for a CBC with hematocrit, a JAK2 V617F test, an erythropoietin level, and oxygen saturation. If you smoke or snore, ask about a sleep study. Do not assume that a high hemoglobin is polycythemia vera; dehydration, smoking, and altitude can raise the number. A hematocrit above 54% in men or above 49% in women deserves a same-week clinical review, not a self-directed donation.
Call the blood center before you go. Ask three questions: Do you accept therapeutic donors with polycythemia? What is the required prescription and target hematocrit? Will the unit be discarded or transfused? Get the answers in writing if possible. If the center does not have a therapeutic donor program, ask your hematologist for a phlebotomy order at a hospital or infusion center. Do not lie on the donor questionnaire; a known diagnosis of polycythemia vera may cause a deferral.
Prepare for the procedure with plain water and a normal meal. Drink about 500 mL of water in the 2 hours before phlebotomy, unless you have fluid restrictions. Avoid alcohol and heavy exercise for 24 hours before and after. Stand up slowly, because a 450-500 mL removal can cause lightheadedness. If you take blood thinners or have heart failure, tell the clinician before the procedure. Bring a list of medicines and your latest CBC.
Track your numbers in one place. Record the date, volume removed, hematocrit before and after, ferritin, and symptoms. A reasonable maintenance target is hematocrit below 45%, with some centers using below 42% for women. Check ferritin every 3-6 months if you are having repeated phlebotomies. Do not take iron supplements unless your hematologist prescribes them; iron can drive more red-cell production in PV. If ferritin is below 15 ng/mL, ask whether the phlebotomy schedule should be adjusted.
Seek urgent care for red-flag symptoms. These can be signs of thrombosis or severe anemia:
- Chest pain, pressure, or shortness of breath at rest.
- Sudden weakness, facial droop, or difficulty speaking.
- Severe headache, confusion, or new visual loss.
- Painful swelling in one leg, especially with redness or warmth.
- Fainting, black stools, or vomiting blood.
- A rapid heartbeat with dizziness or cold, clammy skin.
Limits of the Evidence and Special Cases
The evidence for blood donation in polycythemia is strongest for phlebotomy in PV, not for routine volunteer donation. The CYTO-PV trial enrolled 365 patients and supported a hematocrit target below 45%, but it did not test blood-bank donation as a public supply strategy. For secondary polycythemia, there are no large randomized trials showing that routine phlebotomy improves outcomes when the cause can be treated. In sleep apnea, CPAP can lower hematocrit over weeks to months; in smokers, quitting can reduce carboxyhemoglobin and red-cell mass. Phlebotomy may still be used for symptoms or severe erythrocytosis, but the cause should be treated first.
Special cases need individualized decisions. Pregnancy raises plasma volume, so hematocrit normally falls; phlebotomy is rarely appropriate during pregnancy and may increase iron deficiency. Children with polycythemia are managed by pediatric hematologists, often with weight-based volumes of 10-15 mL/kg rather than a fixed 450-500 mL unit. Adults with severe heart or lung disease may not tolerate a 500 mL volume shift; a smaller, slower procedure or isovolemic exchange may be needed. People living at high altitude may have a physiologically appropriate hematocrit, and donation can worsen exercise capacity. Athletes should avoid phlebotomy before competition because the plasma refill can take 24-48 hours and iron loss can impair training.
Cost and access are real limits. A therapeutic phlebotomy may cost USD 50-200 per session, and some insurance plans cover it only for a diagnosis of PV or hemochromatosis. Blood centers may charge a processing fee even when the unit is discarded. A standard donation is free, but it is not designed for treatment. The practical answer is to ask for a written plan that names the diagnosis, the target hematocrit, the volume, the interval, and the plan for iron monitoring. That plan is what separates safe care from a well-intentioned but risky donation.